Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 12, 2006. The report announces the settlement of a long-standing transfer pricing tax dispute with the US Internal Revenue Service (IRS).
Key Financial Metrics
- Settlement Cost: The final net cash cost to GSK is approximately $3.1 billion.
- Cost Components: This amount includes federal, state, and local taxes, interest, and accounts for the benefit of tax relief on payments made.
- Earnings Impact: The filing states the settlement will not have any significant impact on the Company's reported earnings or tax rate.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Dispute Details
The settlement resolves all issues in dispute regarding transfer pricing for the period 1989-2000, which was scheduled for trial in February 2007. The agreement also covers subsequent years from 2001-2005. GSK had previously made a provision for this dispute, which is why the settlement does not materially alter reported earnings.
Management Commentary and Risks
Management concluded that settling was in the best interests of shareholders to remove the costs and uncertainty of future litigation, despite confidence in the strength of their legal position. The decision was driven by the size of the potential financial exposure and the resources required for continued litigation. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2005 Annual Report.
Investor Verification Checklist
- Verify the exact timing of the $3.1 billion cash outflow in upcoming quarterly cash flow statements.
- Confirm the specific tax provision amounts recorded in prior periods to understand the accounting treatment of the settlement.
- Review the 2005 Annual Report "Risk Factors" section for details on other potential litigation or regulatory exposures.
- Monitor future filings for any additional tax disputes or regulatory actions in other jurisdictions.